Malchoff C D, Reardon G, Javier E C, Rogol A D, McDermott P, Loriaux D L, Malchoff D M
Department of Surgery, University of Connecticut Health Center, Farmington 06030-1110.
J Clin Endocrinol Metab. 1994 Dec;79(6):1632-6. doi: 10.1210/jcem.79.6.7989467.
Generalized glucocorticoid resistance presents with clinical features secondary to excess production of mineralocorticoids and adrenal androgens. It is our hypothesis that these clinical and biochemical features will respond to glucocorticoid therapy. We tested this hypothesis in a boy with generalized glucocorticoid resistance and increased adrenal androgens. Dexamethasone was administered from age 7 6/12 yr until the onset of true puberty at 11 0/12 yr. Serum concentrations of cortisol and adrenal androgens decreased to the normal or near normal range. The accelerated precocity improved. Secondary sex characteristics did not progress; the difference between bone age and chronological age decreased from 3 1/2 yr to 2 yr, and the difference between height age and bone age decreased from 2 yr to 1/2 yr. We conclude that dexamethasone is effective and safe therapy for the sexual precocity of generalized glucocorticoid resistance.
全身性糖皮质激素抵抗表现为继发于盐皮质激素和肾上腺雄激素过量产生的临床特征。我们的假设是,这些临床和生化特征对糖皮质激素治疗会有反应。我们在一名患有全身性糖皮质激素抵抗且肾上腺雄激素增加的男孩中检验了这一假设。地塞米松从7岁6/12岁开始给药,直至11岁0/12岁进入真性青春期。血清皮质醇和肾上腺雄激素浓度降至正常或接近正常范围。加速性早熟得到改善。第二性征未进展;骨龄与实际年龄的差异从3.5岁降至2岁,身高年龄与骨龄的差异从2岁降至0.5岁。我们得出结论,地塞米松是治疗全身性糖皮质激素抵抗性性早熟的有效且安全的疗法。